Periodontal Disease: Etiology, Classification, and Non-Surgical Therapy

Jul 24

Periodontal disease represents a spectrum of inflammatory conditions affecting the supporting structures of the teeth, with severe periodontitis affecting approximately 11.2% of the global adult population—making it the sixth most prevalent disease worldwide. Understanding its multifactorial etiology, current classification framework, and the principles of non-surgical therapy is essential for all dental practitioners. This review synthesizes current evidence on periodontal pathogenesis and the systematic approach to non-surgical management.

1. Etiology of Periodontal Disease

1.1 The Microbial Biofilm Hypothesis

Periodontal disease is a biofilm-induced, host-mediated inflammatory condition. The subgingival biofilm is a complex polymicrobial community organized within an extracellular matrix, exhibiting properties distinct from planktonic bacteria. The current understanding has evolved through several paradigms:

1.2 Key Periodontal Pathogens

Socransky's microbial complexes, established through DNA probe analysis, remain a foundational framework for understanding subgingival ecology. The "red complex"—Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola—is most strongly associated with clinical periodontitis. Aggregatibacter actinomycetemcomitans (formerly Actinobacillus actinomycetemcomitans) is specifically associated with localized aggressive periodontitis, particularly the JP2 leukotoxin-producing clone prevalent in North and West African populations.

1.3 Host Response and Risk Factors

Periodontal tissue destruction is primarily host-mediated. The inflammatory response to the biofilm triggers a cascade of cytokines (IL-1β, TNF-α, IL-6), matrix metalloproteinases (MMP-8, MMP-9), and prostaglandin E2 (PGE2), leading to connective tissue degradation and alveolar bone resorption via RANKL-mediated osteoclast activation. Key risk factors modify this host response:

• Smoking: The most significant modifiable risk factor, increasing periodontitis risk 2.5-6.0 fold. Nicotine impairs neutrophil chemotaxis, phagocytosis, and oxidative burst, while vasoconstriction masks clinical signs of inflammation (reduced bleeding on probing).
• Diabetes mellitus: Hyperglycemia drives formation of advanced glycation end products (AGEs), which bind RAGE receptors on periodontal cells, amplifying inflammatory cytokine production. Periodontitis, in turn, increases systemic inflammatory burden, worsening glycemic control—a bidirectional relationship now well established.
• Genetic factors: IL-1 gene cluster polymorphisms (IL-1A +4845, IL-1B +3954) are associated with increased susceptibility, though genetic testing alone has limited clinical predictive value.
• Stress: Psychological stress impairs immune function through cortisol-mediated pathways and is associated with increased risk of necrotizing periodontal diseases.

2. The 2017 World Workshop Classification

2.1 Framework Overview

The 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, co-organized by the American Academy of Periodontology (AAP) and European Federation of Periodontology (EFP), established a multidimensional staging and grading system that replaced the 1999 chronic/aggressive dichotomy. The new classification integrates:

• Staging (I-IV): Reflects disease severity and complexity of management, based on interproximal clinical attachment loss (CAL), radiographic bone loss, and tooth loss due to periodontitis.
• Grading (A-C): Reflects rate of progression and risk of future progression, based on radiographic bone loss relative to patient age, as well as risk factors like smoking and diabetes.

2.2 Clinical Application

A 45-year-old patient presenting with 6 mm CAL at site 16, radiographic bone loss to the middle third, and 2 teeth lost due to periodontitis would be classified as Stage III, Grade B (if a moderate smoker). This framework communicates both current disease state (Stage) and future risk (Grade), guiding treatment planning toward the appropriate level of intervention.

3. Non-Surgical Periodontal Therapy: Core Principles

3.1 Goals and Philosophy

Non-surgical periodontal therapy (NSPT)—also termed cause-related therapy or Phase I therapy—aims to arrest disease progression by eliminating or substantially reducing the subgingival biofilm. The fundamental goals are:

• Disruption and removal of subgingival biofilm and calculus deposits
• Elimination of plaque-retentive factors (overhanging restorations, open contacts)
• Reduction of periodontal pocket depth to maintainable levels (≤4 mm)
• Resolution of clinical inflammation (reduction in bleeding on probing)
• Patient education and motivation for effective self-performed plaque control

3.2 Scaling and Root Planing (SRP)

Scaling and root planing remains the cornerstone of NSPT. Scaling removes supra- and subgingival plaque and calculus from crown and root surfaces. Root planing aims to remove residual embedded calculus and portions of contaminated cementum and dentin, producing a smooth, biologically compatible root surface. Contemporary evidence-based techniques include:

3.3 Full-Mouth vs. Quadrant-Based Approaches

The debate between full-mouth disinfection (FMD)—completing SRP within 24 hours, often with adjunctive chlorhexidine—and conventional quadrant-by-quadrant therapy has generated substantial literature. A 2015 Cochrane systematic review found no clinically significant differences in pocket depth reduction or CAL gain between approaches at 6-8 months. However, FMD may achieve slightly greater reductions in certain inflammatory biomarkers and could be preferred for patient convenience. The quadrant approach remains practical for most clinical settings, allowing adequate anesthesia coverage and reducing patient discomfort per session.

4. Adjunctive Therapies

4.1 Local Antimicrobial Delivery

Local delivery of antimicrobials directly into periodontal pockets provides high drug concentrations at the target site with minimal systemic exposure. Evidence-based agents include:

• Chlorhexidine chip (PerioChip): 2.5 mg chlorhexidine gluconate in a biodegradable gelatin matrix, providing sustained release over 7-10 days. Meta-analysis shows an additional 0.4-0.6 mm PD reduction in pockets ≥5 mm when combined with SRP.
• Minocycline microspheres (Arestin): 1 mg minocycline HCl encapsulated in bioresorbable poly(glycolide-co-DL-lactide) microspheres, sustaining therapeutic levels for 14 days. Demonstrated efficacy in sites non-responsive to SRP alone.
• Doxycycline hyclate gel (Atridox): 10% doxycycline in a bioabsorbable Atrigel delivery system, providing sustained release for 7 days. Comparable efficacy to other local delivery systems.

4.2 Systemic Antibiotics

Systemic antibiotics are indicated for specific patient populations rather than routine NSPT. The current consensus recommends:

• Amoxicillin 500 mg + Metronidazole 400 mg (3x/day for 7 days): The most evidence-based combination, particularly effective in severe (Stage III-IV, Grade C) periodontitis. A 2020 meta-analysis demonstrated an additional 0.6 mm mean PD reduction and 0.4 mm CAL gain over SRP alone at 12 months.
• Azithromycin 500 mg (1x/day for 3 days): Alternative for penicillin-allergic patients, with comparable efficacy in some studies, though concerns about antibiotic resistance and cardiac risks limit first-line use.
• Doxycycline 100 mg (1x/day for 14-21 days): Effective against A. actinomycetemcomitans, with the added benefit of host-modulatory effects through MMP inhibition at sub-antimicrobial doses (20 mg bid).

Systemic antibiotics should be prescribed only after completion of mechanical debridement to maximize biofilm disruption and minimize the risk of resistant strain selection. They are contraindicated in Stage I-II, Grade A-B periodontitis where SRP alone achieves satisfactory outcomes.

4.3 Host Modulation Therapy

Subantimicrobial-dose doxycycline (SDD, Periostat: 20 mg twice daily) is FDA-approved as an adjunct to SRP for the treatment of chronic periodontitis. By inhibiting collagenase (MMP-8, MMP-9) and other host-derived enzymes without exerting antimicrobial effects, SDD reduces connective tissue breakdown. Clinical trials show an additional 0.3-0.5 mm CAL gain when combined with SRP for 3-9 months, though the clinical significance of this additional benefit remains debated.

5. Re-Evaluation and Maintenance

5.1 The Re-Evaluation Appointment

A critical component of NSPT is the re-evaluation visit, typically scheduled 6-8 weeks after completion of SRP. This timeframe allows for resolution of acute inflammation, re-epithelialization of the sulcular epithelium (requiring approximately 1 week), and connective tissue remodeling (3-4 weeks). At re-evaluation:

• Full-mouth periodontal charting is repeated, comparing to baseline measurements
• Sites with residual PD ≥5 mm and bleeding on probing indicate persistent inflammation requiring further intervention
• Patient plaque control is reassessed; oral hygiene instruction is reinforced
• Decision for surgical vs. continued non-surgical management is made based on residual pocket depth, furcation involvement, and patient compliance

5.2 Supportive Periodontal Therapy (SPT)

Following successful NSPT, patients enter supportive periodontal therapy (SPT)—previously termed periodontal maintenance—with recall intervals tailored to individual risk profiles (typically 3-6 months). SPT compliance is the single most important determinant of long-term periodontal stability. Longitudinal studies demonstrate that patients attending ≥75% of recommended SPT visits experience tooth loss rates of 0.06 teeth/year, compared to 0.43 teeth/year for non-compliant patients. SPT visits include review of medical history, periodontal examination, selective instrumentation of residual or recurrent deep sites, and reinforcement of oral hygiene.

6. Emerging Technologies in Non-Surgical Therapy

• Photodynamic therapy (PDT): Photosensitizer dye activated by a specific wavelength laser generates singlet oxygen, killing bacteria. Evidence for clinically significant additional benefit over SRP remains limited and inconsistent.
• Probiotics: Lactobacillus reuteri and other strains have shown modest reductions in pocket depth and gingival inflammation in pilot studies, but large-scale RCTs are needed.
• Guided biofilm therapy (GBT): A systematic eight-step protocol using air polishing with erythritol powder for biofilm removal, followed by minimally invasive instrumentation. Gaining popularity for improved patient comfort and reduced hard tissue loss.
• Antimicrobial photodynamic therapy combined with nanoparticles: Conjugating photosensitizers to nanoparticles enhances penetration into biofilms, showing improved bacterial killing in vitro.